Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL798608 | 1.00 | SIGMAR1 (0.43) | SIGMAR1CHRNB2CHRNA4CYP11B1CYP11B2 | |
| SCHEMBL31326617 | 0.83 | SIGMAR1 (0.43) | SIGMAR1CHRNB2CHRNA4CYP11B1CYP11B2 | |
| SCHEMBL15088052 | 0.83 | SIGMAR1 (0.43) | SIGMAR1CHRNB2CHRNA4CYP11B1CYP11B2 | |
| SCHEMBL2853230 | 0.78 | — | — | |
| SCHEMBL29704485 | 0.78 | — | — | |
| SCHEMBL27943278 | 0.77 | — | — | |
| Iodide SCHEMBL27382621 | 0.77 | SIGMAR1 (0.40) | SIGMAR1CHRNB2CHRNA4 | |
| Isoquinoline SCHEMBL5124998 | 0.76 | CYP11B1 (0.38) | SIGMAR1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL56690 | 0.71 | TRPA1 (0.42) | CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL16031737 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572356-B2 | Biaryl inhibitors of Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220332705-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2022-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572356-B2 | Biaryl inhibitors of Bruton's tyrosine kinase | ABL1, BTK, LYN | SIGMAR1 4189/4885CHRNB2 3955/4885CHRNA4 4639/4885 |
| US-20220332705-A1 | BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | SIGMAR1 4189/4885CHRNB2 3955/4885CHRNA4 4639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.